CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas

American Journal of Cancer Research

Volumn 6, Issue 2, 2016, Pages 403-424

  Onea, Alexandra S ^a   Jazirehi, Ali R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adoptive cell therapy; Apoptosis; CD19; Chimeric antigen receptor; Hematological malignancies; Immunotherapy; Non Hodgkin's Lymphoma; Resistance; Signal transduction

Indexed keywords

ABC TRANSPORTER; CD40 LIGAND; CHIMERIC ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; CYTOKINE; DASATINIB; DOXORUBICIN; ENZASTAURIN; FOSTAMATINIB; IBRUTINIB; IDELALISIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY MRK 16; PACRITINIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLERIXAFOR; PREDNISONE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RITUXIMAB; RUXOLITINIB; SUNITINIB; T LYMPHOCYTE RECEPTOR; TARIQUIDAR; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADOPTIVE IMMUNOTHERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APLASIA; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DELIRIUM; DRUG BINDING SITE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOXICITY; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; HYPOTENSION; IMMUNOGLOBULIN DEFICIENCY; IMMUNOREGULATION; KIDNEY FAILURE; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; MUCORMYCOSIS; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROTEIN SYNTHESIS INHIBITION; REVIEW; SALVAGE THERAPY; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84981765079     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Hoar Zahm S, Chanock SJ, Cerhan JR and Hartge P. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 2008; 112: 5150-5160.
2. Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H, Kumar V, Chang ET, Rothman N, Cerhan JR, Brooks-Wilson AR, Rehnberg E, Irwan ID, Ryder LP, Brown PN, Bracci PM, Agana L, Riby J, Cozen W, Davis S, Hartge P, Morton LM, Severson RK, Wang SS, Slager SL, Fredericksen ZS, Novak AJ, Kay NE, Habermann TM, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Leach S, Spinelli JJ, Smith MT, Chanock SJ, Padyukov L, Alfredsson L, Klareskog L, Glimelius B, Melbye M, Liu ET, Adami HO, Humphreys K and Liu J. GWAS of Follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011; 7: e1001378.
3. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjosé S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadié M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS and Sampson JN. Etiologic Heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014; 48: 130-144.
4. Theodossiou C and Schwarzenberger P. Non-Hodgkin's Lymphomas. Clin Obstet Gynecol 2002; 43: 820-829.
5. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ and Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
6. Groves FD, Linet MS, Travis LB and Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240-1251.
7. Chiu BC and Hou N. Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res 2015; 165: 1-25.
8. Wang SS, Slager SL, Brennan P, Holly EA, De Sanjose S, Bernstein L, Boffetta P, Cerhan JR, Maynadie M, Spinelli JJ, Chiu BC, Cocco PL, Mensah F, Zhang Y, Nieters A, Dal Maso L, Bracci PM, Costantini AS, Vineis P, Severson RK, Roman E, Cozen W, Weisenburger D, Davis S, Franceschi S, La Vecchia C, Foretova L, Becker N, Staines A, Vornanen M, Zheng T and Hartge P. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (Inter-Lymph). Blood 2007; 109: 3479-3488.
9. Skibola CF, Curry JD and Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007; 92: 960-969.
10. Aboulafia DM, Pantanowitz L and Dezube BJ. AIDS-related non-Hodgkin lymphoma: Still a problem in the era of HAART. AIDS Read 2004; 14: 605-617.
11. Oertel SH and Riess H. Immunosurveillance, immunodeficiency and lymphoproliferations. Recent Results Cancer Res 2002; 159: 1-8.
12. Cleghorn FR, Manns A, Falk R, Hartge P, Hanchard B, Jack N, Williams E, Jaffe E, White F, Bartholomew C and Blattner W. Effect of human T-lymphotropic virus type I infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst 1995; 87: 1009-1014.
13. Knowles DM and Cesarman E. The Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi's sarcoma, malignant lymphoma, and other diseases. Ann Oncol 1997; 8: 123-129.
14. Engels EA, Chatterjee N, Cerhan JR, Davis S, Cozen W, Severson RK, Whitby D, Colt JS and Hartge P. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer 2004; 111: 76-80.
15. Liu YC, Yang YH, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Chang PY and Lin SF. Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies-a nationwide population-based matched-control study in Taiwan. BMC Cancer 2012; 12: 503.
16. De Stefani E, Fierro L, Barrios E and Ronco A. Tobacco, alcohol, diet and risk of non-Hodgkin's lymphoma: a case-control study in Uruguay. Leuk Res 1998; 22: 445-452.
17. Besson H, Brennan P, Becker N, Nieters A, De Sanjose S, Font R, Maynadié M, Foretova L, Cocco PL, Staines A, Vornanen M and Boffetta P. Tobacco smoking, alcohol drinking and non-Hodgkin's lymphoma: a European multicenter case-control study (Epilymph). Int J Cancer 2006; 119: 901-908.
18. Chiu BC, Cerhan JR, Folsom AR, Sellers TA, Kushi LH, Wallace RB, Zheng W and Potter JD. Diet and risk of non-Hodgkin lymphoma in older women. JAMA 1996; 275: 1315-1321.
19. Skibola CF. Obesity, diet and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 392-395.
20. Zhang Y, Sanjose SD, Bracci PM, Morton LM, Wang R, Brennan P, Hartge P, Boffetta P, Becker N, Maynadie M, Foretova L, Cocco P, Staines A, Holford T, Holly EA, Nieters A, Benavente Y, Bernstein L, Zahm SH and Zheng T. Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. Am J Epidemiol 2008; 167: 1321-1331.
21. Melbye M, Adami HO, Hjalgrim H and Glimelius B. Ultraviolet light and non-Hodgkin's lymphoma. Acta Oncol 1996; 35: 655-657.
22. Hartge P, Lim U, Freedman DM, Colt JS, Cerhan JR, Cozen W, Severson RK and Davis S. Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control 2006; 17: 1045-1052.
23. Cocco P, Satta G, Dubois S, Pili C, Pilleri M, Zucca M, 't Mannetje AM, Becker N, Benavente Y, de Sanjosé S, Foretova L, Staines A, Maynadié M, Nieters A, Brennan P, Miligi L, Ennas MG, Boffetta P. Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study. Occup Environ Med 2013; 70: 91-98.
24. Espinosa A, Zock JP, Benavente Y, Boffetta P, Becker N, Brennan P, Cocco P, Foretova L, Maynadié M, Staines A, Nieters A, Kogevinas M, de Sanjose S. Occupational exposure to immunologically active agents and risk for lymphoma: the European Epilymph case-control study. Cancer Epidemiol 2013; 37: 378-384.
25. Coffey J, Hodgson DC, Gospodarowicz MK. Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30: S28-36.
26. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxin, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-2143.
27. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012; 380: 848-857.
28. Bachy E, Salles G. Are we nearing an era of chemotherapy-free management of indolent lymphoma? Clin Cancer Res 2014; 20: 5226-5239.
29. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
30. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
31. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, and Gascoyne RD, Connors JM. Populationbased analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 5165-5169.
32. Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Investig 2008; 28: 55-65.
33. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes del'Adulte. Blood 2010; 116: 2040-2045.
34. Rothe A, Schulz H, Elter T, Engert A, Reiser M. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica 2004; 89: 875-876.
35. Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita K, Hiraoka A, Matsuno Y, Nakamura S, Mori S, Ohashi Y. IDEC-C2B8 Japan Study Group. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 2004; 15: 821-830.
36. van Oers MH. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 2007; 92: 826-833.
37. Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol 2008; 143: 607-621.
38. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 2015; 125: 22-32.
39. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. J Immunol 1975; 174: 2453-2455.
40. Karlitepe A, Ozalp O, Avci CB. New approaches for cancer immunotherapy. Tumour Biol 2015; 36: 4075-4078.
41. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 1984; 81: 6851-6855.
42. Vaughan TJ, Osbourn JK, Tempest PR. Human antibodies by design. Nat Biotechnol 1998; 16: 535-539.
43. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12: 278-287.
44. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47: 115-123.
45. Bonavida B. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol 2014; 41: 667-677.
46. Sitaru C, Thiel J. The need for markers and predictors of Rituximab treatment resistance. Exp Dermatol 2014; 23: 236-237.
47. Magee MS, Snook A. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discov Med 2014; 18: 265-271.
48. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822-1826.
49. Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annu Rev Med 2016; 67.
50. Choudhuri K, Wiseman D, Brown MH, Gould K, van der Merwe PA. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature 2005; 436: 578-582.
51. Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 2015; 33: 9-15.
52. Ramos CA, Savoldo B, Liu E, Gee AP, Mei Z, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. Clinical responses in patients infused with T lymphocytes redirected to target k-light immunoglobulin chain. ASH Annual Meeting and Exposition Abstract. Blood 2013; 122: 506.
53. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517.
54. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra25.
55. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK, Dotti G. T lymphocytes redirected against the k light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006; 108: 3890-3897.
56. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31: 71-75.
57. Federov VD, Themeli M, Sadelain M. PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013; 5: 215ra172.
58. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365: 1673-1683.
59. Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One 2013; 8: e82742.
60. Moreau T, Bardin F, Imbert J, Chabannon C, Tonnelle C. Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Molecular Ther 2004; 10: 45-56.
61. Thierry-Mieg D, Thierry-Mieg J. AceView: a comprehensive cDNA-supported gene and transcripts annotation-Homo sapiens complex locus CD19, encoding CD19 molecule. Genome Biol 2006; 7: S12.1-14.
62. Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes: A new member of the immunoglobulin superfamily. J Immunol 1989; 143: 712-717.
63. Zhou LJ, Ord DC, Omori SA, Tedder TF. Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes. Immunogenetics 1992; 35: 102-111.
64. Weiland J, Elder A, Forster V, Heidenreich O, Koschmieder S, Vormoor J. CD19: A multifunc tional immunological target molecule and its implications for B lineage acute lymphoblastic leukemia. Pediatr Blood Cancer 2015; 62: 1144-1148.
65. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983; 131: 244-250.
66. Schriever F, Freedman AS, Freeman G, Messner E, Lee G, Daley J, Nadler LM. Isolated human follicular dendritic cells display a unique antigenic phenotype. J Exp Med 1989; 169: 2043-2058.
67. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, Tedder TF. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000; 13: 47-57.
68. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000; 18: 393-422.
69. Mattila PK, Feest C, Depoil D, Treanor B, Montaner B, Otipoby KL, Carter R, Justement LB, Bruckbauer A, Batista FD. The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling. Immunity 2013; 38: 461-474.
70. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992; 256: 105-107.
71. Otero DC, Anzelon AN, Rickert RC. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19 dependent survival signals. J Immunol 2003; 170: 73-83.
72. Van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354: 1901-1912.
73. Kanegane H, Agematsu K, Futatani T, Sira MM, Suga K, Sekiguchi T, van Zelm MC, Miyawaki T. Novel mutations in a Japanese patient with CD19 deficiency. Genes Immun 2007; 8: 663-670.
74. Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun 2005; 8: 55-90.
75. Manning BD, Cantley LC. AKT/PKB signa-l ing: Navigating downstream. Cell 2007; 129: 1261-1274.
76. Reth M, Nitschke L, Hikida M, Kurosaki T. Structure and signaling function of the B-cell antigen receptor and its coreceptors. Molecular Biology of B Cells, Second Edition. Edited by Alt FW, Honjo T, Radbruch A, Reth M. London: Academic Press; 2015. pp. 151-164.
77. Ghorashian S, Pule M, Amrolia P. CD19 chimeric antigen receptor T cell therapy for haematological malignancies. Br J Haematol 2015; 169: 463-478.
78. Kim SJ. Lymphoma stem cells: A step toward a new therapeutic target. Korean J Hematol 2011; 46: 211-213.
79. Lee MR, Ju HJ, Kim BS, Ko YH, Kim WS, Kim SJ. Isolation of side population cells in B-cell non-Hodgkin's lymphomas. Acta Haematol 2013; 129: 10-17.
80. Green MR, Alizadeh AA. Common progenitor cells in mature B-cell malignancies: implications for therapy. Curr Opin Hematol 2014; 21: 333-340.
81. Kim SM, Lee ST, Ryu KJ, Kim HJ, Kim SH, Yoo KH, Ko YH, Kim WS, Kim SJ. Clinical Relevance of CD45+/CD19-Stem-like Tumor Cells in Patients with Mantle Cell Lymphoma: A Single Center Experience. Blood 2014; 124: 1622.
82. Evans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol 2015; 171: 205-209.
83. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, Kutok JL, Kearney JF, Otipoby KL, Rajewsky K. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139: 573-586.
84. Cozma D, Yu D, Hodawadekar S, Azvolinsky A, Grande S, Tobias JW, Metzgar MH, Paterson J, Erikson J, Marafioti T, Monroe JG, Atchison ML, Thomas-Tikhonenko A. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest 2007; 117: 2602-2610.
85. Arita A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Gabrilove J, Brody JD. Signaling pathways in lymphoma: pathogenesis and therapeutic targets. Future Oncol 2013; 9: 1549-1571.
86. Fellbaum C, Radaszkiewicz T, Ruhri C, Pütz B, Lehmacher W, Höfler H. c-myc mRNA expression in non-Hodgkin's lymphomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1992; 62: 61-68.
87. Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012; 122: 2257-2266.
88. Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol 2012; 189: 2318-2325.
89. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-4828.
90. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-4102.
91. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-2720.
92. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
93. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor modified T-cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
94. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapyrefractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540-549.
95. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.
96. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-528.
97. Van Zelm MC, Smet J, Adams B, Mascart F, Schandené L, Janssen F, Ferster A, Kup CC, Levy S, van Dongen JJ, van der Burg M. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010; 120: 1265-1274.
98. Sotillo E, Barrett D, Bagashev A, Black K, Lanauze C, Oldridge D, Sussman R, Harrington C, Chung EY, Hofmann TJ, Maude SL, Martinez NM, Raman P, Ruella M, Allman D, Jacoby E, Fry T, Barash Y, Lynch KW, Mackall C, Maris J, Grupp SA, Thomas-Tikhonenko A. Alternative splicing of CD19 mRNA in leukemias escaping CART-19 immunotherapy eliminates the cognate epitope and contributes to treatment failure. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research. Philadelphia, PA: AACR. Cancer Res 2015; 75: 3143.
99. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011; 117: 1781-1791.
100. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005; 45: 872-877.
101. Jazirehi AR. Functional complementation, molecular targeted strategies, and chemo/immune sensitization in cancer treatment: hurdles and solutions. Current Drug Delivery 2012; 9: 1-4.
102. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-1132.
103. Karlsson H, Lindqvist AC, Fransson M, Paul-Wetterberg G, Nilsson B, Essand M, Nilsson K, Frisk P, Jernberg-Wiklund H, Loskog A. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Cancer Gene Ther 2013; 20: 386-393.
104. Karlsson H. CD19-targeting CAR T Cells for Treatment of B Cell Malignancies. From Bench to Bedside. Digital Comprehensive Summaries of Uppsala. Dissertations from the Faculty of Medicine Uppsala, Sweden: Acta Universitatis Upsaliensis 2014; 1031: 72.
105. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320: 1047-1054.
106. Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol 2006; 6: 682-692.
107. Urban D, Thanabalasingam U, Stibenz D, Kaufmann J, Meyborg H, Fleck E, Gräfe M, Stawowy P. CD40/CD40L interaction induces E-selectin dependent leukocyte adhesion to human endothelial cells and inhibits endothelial cell migration. Biochem Biophys Res Commun 2011; 404: 448-452.
108. Enblad G, Karlsson H, Loskog ASI. CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma. Hum Gene Ther 2015; 26: 498-505.
109. Scott DW, Gascoyne RD. The tumor microenvironment in B cell lymphomas. Nat Rev Cancer 2014; 14: 517-534.
110. Hegde M, Corder A, Chow KKH, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant F, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottachalk S, Yvon E, Ahmed N. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013; 21: 2087-2101.
111. Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control 2004; 11: 97-104.
112. Kim SM, Lee ST, Ryu KJ, Kim HJ, Kim SH, Ko YH, Kim WS, Kim SJ. A subset of CD45+/CD19-cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma. Leuk Lymphoma 2015; 56: 3052-3057.
113. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2008; 23: 43-52.
114. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, Kreuger J, Dimberg A. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. FASEB J 2015; 29: 227-238.
115. Chen K, Huang Y, Chen J. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin 2013; 34: 732-740.
116. Sims-Mourtada J, Izzo JG, Ajani J, Chao KSC. Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007; 26: 5674-5679.
117. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009; 136: 21-29.
118. Ritchie TK, Kwon H, Atkins WM. Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2. J Biol Chem 2011; 286: 39489-39496.
119. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2013; 369: 32-42.
120. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, Mc-Greivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2013; 369: 507-516.
121. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL,Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 2015; 372: 1430-1440.
122. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
123. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of aphase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
124. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008; 100: 580-595.
125. Keuling AM, Felton KEA, Parker AAM, Akbari M, Andrew SE, Tron VA. RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway. PLoS One 2009; 4: e6651.
126. Zauli G, Corallini F, Zorzet S, Grill V, Marzari R, Secchiero P. In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAILR2 minibody. Invest New Drugs 2012; 30: 405-407.
127. Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S, Newsom-Davis T, von Karstedt S, Graves J, Walczak H. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene 2015; 30: 2138-2144.
128. Kobayashi E, Kishi H, Ozawa T, Hamana H, Nakagawa H, Jin A, Lin Z, Muraguchi A. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. Biochem Biophys Res Commun 2014; 453: 798-803.
129. Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, Purdon T, Pegram HJ, Brentjens RJ. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 2015; 23: 769-778.
130. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 2015; 21: 524-529.
131. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308.
132. Zhang T, Cao L, Xie J, Shi N, Zhang Z, Luo Z, Yue D, Zhang Z, Wang L, Han W, Xu Z, Chen H, Zhang Y. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a metaanalysis. Oncotarget 2015; 6: 33961-33971.
133. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J 2015; 20: 112-118.
134. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010; 16: 1245-1256.
135. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013; 122: 2965-2973.
136. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122: 4129-4139.
137. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014; 123: 3750-9.
138. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-528.
139. Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med 2015; 373: 1040-1047.
140. Schuster SJ, Svoboda J, Nasta S, Porter DL, Mato A, Shah GD, Landsburg DJ, Chong EA, Lacey SF, Melenhorst JJ, Chew A, Hasskarl J, Shah NN, Wasik MA, Marcucci K, Zheng Z, Levine B, June CH. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. J Clin Oncol 2015; 33 suppl.
141. Sauter CS, Riviere I, Bernal Y, Wang X, Purdon T, Yoo S, Moskowitz CH, Giralt S, Matasar MJ, Curran KJ, Park JH, Sadelain M, Brentjens RJ. Phase I trial of 19-28z chimeric antigen modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol 2015; 33 suppl: abstract 8515.